SCHEMBL3135116

SCHEMBL3135116

Nc1cnc(C(=O)O)cc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.48
ASPH Q12797 3/20 0.48
KDM8 Q8N371 2/20 0.48
P4HTM Q9NXG6 2/20 0.43
P4HA1 P13674 1/20 0.43
MIF P14174 1/20 0.43
ALDH1A1 P00352 5/20 0.42
KDM6B O15054 1/20 0.42
TET3 O43151 1/20 0.42
KDM4A O75164 1/20 0.42
BBOX1 O75936 1/20 0.42
MAPT P10636 1/20 0.42
KDM5A P29375 1/20 0.42
KDM5C P41229 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
TET2 Q6N021 1/20 0.42
ALKBH5 Q6P6C2 1/20 0.42
KDM7A Q6ZMT4 1/20 0.42
TET1 Q8NFU7 1/20 0.42
EGLN2 Q96KS0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31052887 1.00 KDM4E (0.48) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL31052884 1.00 KDM4E (0.48) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL5917874 0.83 KDM4E (0.46) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL3242847 0.83 KDM4E (0.55) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL9319920 0.83 KDM4E (0.60) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL31513879 0.81 KDM4E (0.47) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL21989487 0.81 KDM4E (0.63) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL12384971 0.81 UHRF1 (0.52) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL31090134 0.81 KDM4E (0.47) KDM4EASPHKDM8P4HTMP4HA1
SCHEMBL12489210 0.81 GABRP (0.47) KDM4EASPHKDM8P4HTMP4HA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3782997-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES Galapagos N.V. (BE) 2021-02-24 EP disclosed
US-8598190-B2 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-12-03 US disclosed
CN-101203518-B Fluorene derivative, composition containing the same and use thereof AVENTIS PHARMA SA 2013-07-24 CN disclosed
CN-102164922-A 3H-imidazo [4,5-C ] pyridine-6-carboxamides as anti-inflammatory agents BOEHRINGER INGELHEIM INT 2011-08-24 CN disclosed
WO-2010034798-A1 3H-IMIDAZO [4, 5-C] PYRIDINE-6-CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed
US-7674795-B2 Fluorene derivatives, composition containing said derivatives and the use thereof AVENTIS PHARMA SA (FR) 2010-03-09 US disclosed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US disclosed
CN-101203518-A Novel fluorene derivatives, compositions containing same and uses thereof AVENTIS PHARMA SA (FR) 2008-06-18 CN disclosed
US-7256287-B2 Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation AVANIR PHARMACEUTICALS (US) 2007-08-14 US disclosed
US-7256287-B2 Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation AVANIR PHARMACEUTICALS (US) 2007-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 KDM4E 3419/4885ASPH 4618/4885KDM8 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.